Document Detail


Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests.
MedLine Citation:
PMID:  8769509     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Inhaled nitric oxide (NO) has been shown to be a selective pulmonary vasodilator in certain patients with primary pulmonary hypertension (PPH).
OBJECTIVES: The purpose of this study was to design and test a system for delivery of NO to awaken, ambulatory patients with PPH and to evaluate this system in the home setting.
METHODS: The ambulatory delivery system consisted of a tank of 80 ppm of NO (balance N2), a modified gas-pulsing device, and nasal cannulas. The pulsing device was set to deliver NO for 0.1 s at the beginning of each inspiration.
RESULTS: Using this system, eight patients with PPH were studied with pulmonary artery catheters in place. Inhalation of NO led to significant reductions in both mean pulmonary arterial pressure (PAPm) (51 +/-12 to 43 +/- 10 mm Hg; p=0.001) and pulmonary vascular resistance (PVR) (790 +/- 285 to 620 +/- 208 dyne x s x cm-5; p=0.01). Three of the eight patients had both greater than 20% and greater than 30% decreases in PAPm and PVR, respectively. No exhaled NO or N02 was detectable in any of the eight patients. One patient was discharged home from the hospital on a regimen of inhaled NO. At 9 months, no adverse effects were noted and the system was working well.
CONCLUSIONS: Pulsed delivery of inhaled NO to ambulatory patients with PPH, via nasal prongs, is feasible and, in some patients, leads to significant improvement in pulmonary hypertension. Inhaled 09NO, therefore, may have a role in the long-term treatment of patients with PPH.
Authors:
R N Channick; J W Newhart; F W Johnson; P J Williams; W R Auger; P F Fedullo; K M Moser
Related Documents :
11732459 - Efficacy and cost-effectiveness of bronchial arterial embolisation in the treatment of ...
15751279 - The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lun...
2392789 - Effect of lung t lymphocytes on fibroblasts in idiopathic pulmonary fibrosis and extrin...
2661259 - Lung function in allogeneic bone marrow transplantation recipients.
18717519 - Redefining idiopathic interstitial lung disease into occupational lung diseases by anal...
19960789 - Serum ca 15-3 is increased in pulmonary fibrosis.
22445069 - Gait and motor imagery of gait in early schizophrenia.
9659169 - Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis...
23669409 - Life-threatening hypokalemia following rapid correction of respiratory acidosis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Chest     Volume:  109     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  1996 Jun 
Date Detail:
Created Date:  1996-10-03     Completed Date:  1996-10-03     Revised Date:  2011-01-14    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1545-9     Citation Subset:  AIM; IM    
Affiliation:
Pulmonary and Critical Care Division, University of California at San Diego Medical Center, 92103, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Blood Pressure
Cardiac Output
Home Care Services
Humans
Hypertension, Pulmonary / drug therapy*,  physiopathology
Nitric Oxide / administration & dosage*
Pulmonary Artery / physiopathology
Pulmonary Wedge Pressure
Vascular Resistance
Chemical
Reg. No./Substance:
10102-43-9/Nitric Oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is resection of bronchiectasis beneficial in patients with primary ciliary dyskinesia?
Next Document:  The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans.